

# Sarah J Welsh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/330193/publications.pdf>

Version: 2024-02-01

20  
papers

487  
citations

1162367

8  
h-index

794141

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. <i>BJU International</i> , 2022, 130, 244-253.	1.3	5
2	Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. <i>BJU International</i> , 2022, 129, 290-303.	1.3	11
3	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. <i>British Journal of Cancer</i> , 2022, 126, 204-210.	2.9	1
4	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2022, 22, 99.	1.1	14
5	Hyperpolarized <sup>13</sup> C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study. <i>Cancers</i> , 2022, 14, 335.	1.7	18
6	“Know thyself”™ “ host factors influencing cancer response to immune checkpoint inhibitors. <i>Journal of Pathology</i> , 2022, 257, 513-525.	2.1	8
7	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. <i>Kidney Cancer</i> , 2022, 6, 115-127.	0.2	2
8	A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3032-3041.	3.2	7
9	A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). <i>British Journal of Cancer</i> , 2022, 127, 1051-1060.	2.9	17
10	A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. <i>European Urology Focus</i> , 2021, 7, 407-419.	1.6	12
11	Stromal-driven and Amyloid $\beta$ -dependent induction of neutrophil extracellular traps modulates tumor growth. <i>Nature Communications</i> , 2021, 12, 683.	5.8	77
12	Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. <i>PLoS ONE</i> , 2021, 16, e0258988.	1.1	4
13	The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. <i>Biology</i> , 2020, 9, 74.	1.3	2
14	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. <i>World Journal of Urology</i> , 2018, 36, 417-425.	1.2	24
15	Intensity Modulated Radiotherapy is a Well-Tolerated and Effective Treatment for the Long-Term Control of Intra-Abdominal and Retroperitoneal Oligometastatic Renal Cell Cancer. <i>Kidney Cancer</i> , 2018, 2, 103-113.	0.2	0
16	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	1.2	10
17	Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy. <i>BMC Research Notes</i> , 2015, 8, 524.	0.6	4
18	Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 122-136.	1.4	267

#	ARTICLE	IF	CITATIONS
19	Management of the patient with neutropenic sepsis. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT <sub>3</sub> /Overlock	0.2	1
20	Assessment of the patient with neutropenic sepsis. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBT <sub>3</sub> /Overlock	0.2	10 Tf 50